Loading...
Thumbnail Image
Publication

A Quality Improvement Project to Assess the Value of Pharmacogenomic Testing in Adults Diagnosed with Major Depression

Abstract
Abstract Background: Treatment of major depression follows the guidelines from evidence-based medicine established algorithms; however, 50% of patients diagnosed with major depressive disorder do not respond to their first medication trial, and 70% may go through four treatment attempts before achieving remission. Purpose: To demonstrate the value of pharmacogenomic testing as a treatment-guidance technology in patients with resistant depression and assess healthcare providers' motivation to adopt the technology. Methods: A retrospective chart review of (N = 73) patients' treatment response measured by the pre-post PHQ-9 depression scale after pharmacogenomic guided medication intervention with descriptive statistics and paired t-test. The project also assessed providers' motivation to adopt and use pharmacogenomic testing by completing the providers' motivation scale (PMA) before and after viewing an educational session on the subject. Results: A significant improvement in mood with a mean decrease of 10 points in the post PHQ-9 scores ( p = .000 < .001) in 53% of the subjects, and 33% had scores that ranked within remission. Most patients (60%) responded to 1.3 medications post pharmacogenomic treatment. The providers were motivated to learn new technology and gain knowledge derived from current information for patient care. Conclusions: These are significant findings corresponding to the new evidence research in pharmacogenomics supporting the use of the technology as a therapeutic resource for treatment-resistant depression patients. Keywords: pharmacogenomics, psychiatry, major depression, nursing, innovation adoption
Type
open
article
Date
2021-01-01
Publisher
Degree
Rights
License
http://creativecommons.org/licenses/by-nc-nd/3.0/